Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Current Oncology Reports
Published in: Current Oncology Reports 8/2022

Open Access 06-04-2022 | Ependymoma | Neuro-oncology (KS Nevel, Section Editor)

Ependymoma: Evaluation and Management Updates

Authors: Roberta Rudà, Francesco Bruno, Alessia Pellerino, Riccardo Soffietti

Published in: Current Oncology Reports | Issue 8/2022

Login to get access

Abstract

Purpose of Review

To review state of art and relevant advances in the molecular genetics and management of ependymomas of children and adults.

Recent Findings

Ependymomas may occur either in the brain or in the spinal cord. Compared with intracranial ependymomas, spinal ependymomas are less frequent and exhibit a better prognosis. The new WHO classification of CNS tumors of 2021 has subdivided ependymomas into different histomolecular subgroups with different outcome. The majority of studies have shown a major impact of extent of resection; thus, a complete resection must be performed, whenever possible, at first surgery or at reoperation. Conformal radiotherapy is recommended for grade 3 or incompletely resected grade II tumors. Proton therapy is increasingly employed especially in children to reduce the risk of neurocognitive and endocrine sequelae. Craniospinal irradiation is reserved for metastatic disease. Chemotherapy is not useful as primary treatment and is commonly employed as salvage treatment for patients failing surgery and radiotherapy.

Summary

Standard treatments are still the mainstay of treatment: the discovery of new druggable pathways will hopefully increase the therapeutic armamentarium in the near future.
Literature
1.
Ostrom QT, Patil N, Cioffi G, Waite K, Kruchko C, Barnholtz-Sloan JS. CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2013–2017. Neuro Oncol. 2020;22(12 Suppl 2):iv1-iv96.
2.
McGuire CS, Sainani KL, Fisher PG. Incidence patterns for ependymoma: a surveillance, epidemiology, and end results study. J Neurosurg. 2009;110(4):725–9.PubMedCrossRef
3.
Rudà R, Reifenberger G, Frappaz D, et al. EANO guidelines for the diagnosis and treatment of ependymal tumors. Neuro Oncol. 2018;20(4):445–56.PubMedCrossRef
4.
Wani K, Armstrong TS, Vera-Bolanos E, et al; Collaborative Ependymoma Research Network. A prognostic gene expression signature in infratentorial ependymoma. Acta Neuropathol. 2012;123(5):727–738.
5.
Raghunathan A, Wani K, Armstrong TS, et al; Collaborative Ependymoma Research Network. Histological predictors of outcome in ependymoma are dependent on anatomic site within the central nervous system. Brain Pathol. 2013;23(5):584–594.
6.
7.
• Jünger ST, Timmermann B, Pietsch T. Pediatric ependymoma: an overview of a complex disease. Childs Nerv Syst. 2021;37(8):2451–63. (An exhaustive overview of molecular and therapeutic aspects of pediatric ependymomas.)PubMedPubMedCentralCrossRef
8.
Pajtler KW, Witt H, Sill M, Jones DT, et al. Molecular classification of ependymal tumors across all CNS compartments, histopathological grades, and age groups. Cancer Cell. 2015;27(5):728–43.PubMedPubMedCentralCrossRef
9.
Louis DN, Perry A, Reifenberger G, et al. The 2016 World Health Organization classification of tumors of the central nervous system: a summary. Acta Neuropathol. 2016;131(6):803–20.PubMedCrossRef
10.
Ellison DW, Aldape KD, Capper D, et al. cIMPACT-NOW update 7: advancing the molecular classification of ependymal tumors. Brain Pathol. 2020;30(5):863–6.PubMedPubMedCentral
11.
•• Louis DN, Perry A, Wesseling P, et al. The 2021 WHO classification of tumors of the central nervous system: a summary. Neuro Oncol. 2021;23(8):1231–51. (The new WHO classification of CNS tumors, including ependymomas.)PubMedPubMedCentralCrossRef
12.
• Merchant TE, Bendel AE, Sabin ND, et al. Conformal radiation therapy for pediatric ependymoma, chemotherapy for incompletely resected ependymoma, and observation for completely resected, supratentorial ependymoma. J Clin Oncol. 2019;37(12):974–83. (A clinical trial reporting the value of observation after complete resection of supratentorial pediatric ependymomas.)PubMedPubMedCentralCrossRef
13.
Upadhyaya SA, Robinson GW, Onar-Thomas A, et al. Molecular grouping and outcomes of young children with newly diagnosed ependymoma treated on the multi-institutional SJYC07 trial. Neuro Oncol. 2019;21(10):1319–30.PubMedPubMedCentralCrossRef
14.
• Massimino M, Barretta F, Modena P, et al. Second series by the Italian Association of Pediatric Hematology and Oncology of children and adolescents with intracranial ependymoma: an integrated molecular and clinical characterization with a long-term follow-up. Neuro Oncol. 2021;23(5):848–57. (A multi-institutional study reporting long-term results of intracranial pediatric ependymomas.)PubMedCrossRef
15.
• Andreiuolo F, Varlet P, Tauziède-Espariat A, et al. Childhood supratentorial ependymomas with YAP1-MAMLD1 fusion: an entity with characteristic clinical, radiological, cytogenetic and histopathological features. Brain Pathol. 2019;29(2):205–16. (First description of supratentorial YAP1 fusion ependymoma.)PubMedCrossRef
16.
17.
• Baroni LV, Sundaresan L, Heled A, et al. Ultra high-risk PFA ependymoma is characterized by loss of chromosome 6q. Neuro Oncol. 2021;23(8):1360–70. (Study suggesting a molecular subdivision of posterior fossa ependymoma of type A.)PubMedPubMedCentralCrossRef
18.
Swanson AA, Raghunathan A, Jenkins RB, et al. Spinal cord ependymomas with MYCN amplification show aggressive clinical behavior. J Neuropathol Exp Neurol. 2019;78(9):791–7.PubMedCrossRef
19.
• Raffeld M, Abdullaev Z, Pack SD, et al. High level MYCN amplification and distinct methylation signature define an aggressive subtype of spinal cord ependymoma. Acta Neuropathol Commun. 2020;8(1):101. (Study describing extensively the molecular characteristics of MYCN amplified spinal ependymoma.)PubMedPubMedCentralCrossRef
20.
Lopez-Rivera V, Dono A, Abdelkhaleq R, et al. Treatment trends and overall survival in patients with grade II/III ependymoma: the role of tumor grade and location. Clin Neurol Neurosurg. 2020;199:106282.
21.
22.
Nowak J, Seidel C, Pietsch T, et al. Systematic comparison of MRI findings in pediatric ependymoblastoma with ependymoma and CNS primitive neuroectodermal tumor not otherwise specified. Neuro Oncol. 2015;17(8):1157–65.PubMedPubMedCentralCrossRef
23.
Jaremko JL, Jans LB, Coleman LT, Ditchfield MR. Value and limitations of diffusion-weighted imaging in grading and diagnosis of pediatric posterior fossa tumors. AJNR Am J Neuroradiol. 2010;31(9):1613–6.PubMedPubMedCentralCrossRef
24.
Tensaouti F, Ducassou A, Chaltiel L, et al; radiotherapy committee of the French Society for Childhood Cancer (SFCE). Prognostic and predictive values of diffusion and perfusion MRI in paediatric intracranial ependymomas in a large national study. Br J Radiol. 2016;89(1066):20160537.
25.
Engelhard HH, Villano JL, Porter KR, et al. Clinical presentation, histology, and treatment in 430 patients with primary tumors of the spinal cord, spinal meninges, or cauda equina. J Neurosurg Spine. 2010;13(1):67–77.PubMedCrossRef
26.
• Klawinski D, Indelicato DJ, Hossain J, Sandler E. Surveillance imaging in pediatric ependymoma. Pediatr Blood Cancer. 2020;67(11):e28622. (The unique study describing surveillance neuroimaging in pediatric ependymomas.)
27.
Good CD, Wade AM, Hayward RD, et al. Surveillance neuroimaging in childhood intracranial ependymoma: how effective, how often, and for how long? J Neurosurg. 2001;94(1):27–32.PubMedCrossRef
28.
Pejavar S, Polley MY, Rosenberg-Wohl S, et al. Pediatric intracranial ependymoma: the roles of surgery, radiation and chemotherapy. J Neurooncol. 2012;106(2):367–75.PubMedCrossRef
29.
Massimino M, Miceli R, Giangaspero F, et al. Final results of the second prospective AIEOP protocol for pediatric intracranial ependymoma. Neuro Oncol. 2016;18(10):1451–60.PubMedPubMedCentralCrossRef
30.
Massimino M, Solero CL, Garrè ML, et al. Second-look surgery for ependymoma: the Italian experience. J Neurosurg Pediatr. 2011;8(3):246–50.PubMedCrossRef
31.
Millward CP, Mallucci C, Jaspan T, Macarthur D, Heyward R, Cox T, Chong K, Grundy RG. Assessing ‘second-look’ tumour resectability in childhood posterior fossa ependymoma-a centralised review panel and staging tool for future studies. Childs Nerv Syst. 2016;32(11):2189–96.PubMedCrossRef
32.
Merchant TE, Li C, Xiong X, Kun LE, Boop FA, Sanford RA. Conformal radiotherapy after surgery for paediatric ependymoma: a prospective study. Lancet Oncol. 2009;10(3):258–66.PubMedPubMedCentralCrossRef
33.
Koshy M, Rich S, Merchant TE, Mahmood U, Regine WF, Kwok Y. Post-operative radiation improves survival in children younger than 3 years with intracranial ependymoma. J Neurooncol. 2011;105(3):583–90.PubMedCrossRef
34.
Tensaouti F, Ducassou A, Chaltiel L, et al; radiotherapy committee of the French Society for Childhood Cancer (SFCE). Patterns of failure after radiotherapy for pediatric patients with intracranial ependymoma. Radiother Oncol. 2017;122(3):362–367.
35.
Aggarwal R, Yeung D, Kumar P, Muhlbauer M, Kun LE. Efficacy and feasibility of stereotactic radiosurgery in the primary management of unfavorable pediatric ependymoma. Radiother Oncol. 1997;43(3):269–73.PubMedCrossRef
36.
Conter C, Carrie C, Bernier V, et al. Intracranial ependymomas in children: Society of Pediatric Oncology experience with postoperative hyperfractionated local radiotherapy. Int J Radiat Oncol Biol Phys. 2009;74(5):1536–42.PubMedCrossRef
37.
Massimino M, Gandola L, Giangaspero F, et al; AIEOP Pediatric Neuro-Oncology Group. Hyperfractionated radiotherapy and chemotherapy for childhood ependymoma: final results of the first prospective AIEOP (Associazione Italiana di Ematologia-Oncologia Pediatrica) study. Int J Radiat Oncol Biol Phys. 2004;58(5):1336–1345.
38.
Leroy R, Benahmed N, Hulstaert F, Van Damme N, De Ruysscher D. Proton therapy in children: a systematic review of clinical effectiveness in 15 pediatric cancers. Int J Radiat Oncol Biol Phys. 2016;95(1):267–78.PubMedCrossRef
39.
Sato M, Gunther JR, Mahajan A, et al. Progression-free survival of children with localized ependymoma treated with intensity-modulated radiation therapy or proton-beam radiation therapy. Cancer. 2017;123(13):2570–8.PubMedCrossRef
40.
• Indelicato DJ, Ioakeim-Ioannidou M, Bradley JA, et al. Proton therapy for pediatric ependymoma: mature results from a bicentric study. Int J Radiat Oncol Biol Phys. 2021;110(3):815–20. (Detailed multicenter retrospective study on efficacy and adverse events of proton therapy in pediatric ependymomas.)PubMedCrossRef
41.
Khatua S, Ramaswamy V, Bouffet E. Current therapy and the evolving molecular landscape of paediatric ependymoma. Eur J Cancer. 2017;70:34–41.PubMedCrossRef
42.
Grill J, Le Deley MC, Gambarelli D, et al; French Society of Pediatric Oncology. Postoperative chemotherapy without irradiation for ependymoma in children under 5 years of age: a multicenter trial of the French Society of Pediatric Oncology. J Clin Oncol. 2001;19(5):1288–1296.
43.
Grundy RG, Wilne SA, Weston CL, et al; Children’s Cancer and Leukaemia Group (formerly UKCCSG) Brain Tumour Committee. Primary postoperative chemotherapy without radiotherapy for intracranial ependymoma in children: the UKCCSG/SIOP prospective study. Lancet Oncol. 2007;8(8):696–705.
44.
Garvin JH Jr, Selch MT, Holmes E, et al; Children’s Oncology Group. Phase II study of pre-irradiation chemotherapy for childhood intracranial ependymoma. Children’s Cancer Group protocol 9942: a report from the Children’s Oncology Group. Pediatr Blood Cancer. 2012;59(7):1183–1189.
45.
Venkatramani R, Ji L, Lasky J, et al. Outcome of infants and young children with newly diagnosed ependymoma treated on the “Head Start” III prospective clinical trial. J Neurooncol. 2013;113(2):285–91.PubMedPubMedCentralCrossRef
46.
Lötsch D, Kirchhofer D, Englinger B, et al. Targeting fibroblast growth factor receptors to combat aggressive ependymoma. Acta Neuropathol. 2021;142(2):339–60.PubMedPubMedCentralCrossRef
47.
Rudà R, Gilbert M, Soffietti R. Ependymomas of the adult: molecular biology and treatment. Curr Opin Neurol. 2008;21(6):754–61.PubMedCrossRef
48.
Reni M, Brandes AA, Vavassori V, et al. A multicenter study of the prognosis and treatment of adult brain ependymal tumors. Cancer. 2004;100(6):1221–9.PubMedCrossRef
49.
Rogers L, Pueschel J, Spetzler R, et al. Is gross-total resection sufficient treatment for posterior fossa ependymomas? J Neurosurg. 2005;102(4):629–36.PubMedCrossRef
50.
Metellus P, Barrie M, Figarella-Branger D, et al. Multicentric French study on adult intracranial ependymomas: prognostic factors analysis and therapeutic considerations from a cohort of 152 patients. Brain. 2007;130(Pt 5):1338–49.PubMedCrossRef
51.
Metellus P, Guyotat J, Chinot O, et al. Adult intracranial WHO grade II ependymomas: long-term outcome and prognostic factor analysis in a series of 114 patients. Neuro Oncol. 2010;12(9):976–84.PubMedPubMedCentralCrossRef
52.
Hollon T, Nguyen V, Smith BW, Lewis S, Junck L, Orringer DA. Supratentorial hemispheric ependymomas: an analysis of 109 adults for survival and prognostic factors. J Neurosurg. 2016;125(2):410–8.PubMedCrossRef
53.
• Zhao F, Wu T, Wang LM, Zhang J, Zhang H, Li SW, Zhang S, Li P, Wang B, Luo L, Liu PN. Survival and prognostic factors of adult intracranial ependymoma: a single-institutional analysis of 236 patients. Am J Surg Pathol. 2021;45(7):979–87. (A huge retrospective analysis of outcome in adult intracranial ependymoma.)PubMed
54.
Spagnoli D, Tomei G, Ceccarelli G, et al. Combined treatment of fourth ventricle ependymomas: report of 26 cases. Surg Neurol. 2000;54(1):19–26; discussion 26.
55.
Oya N, Shibamoto Y, Nagata Y, Negoro Y, Hiraoka M. Postoperative radiotherapy for intracranial ependymoma: analysis of prognostic factors and patterns of failure. J Neurooncol. 2002;56(1):87–94.PubMedCrossRef
56.
• Wee CW, Kim IH, Park CK, et al. Postoperative radiotherapy for WHO grade II-III intracranial ependymoma in adults: an intergroup collaborative study (KROG 18–06/KNOG 18–01). Radiother Oncol. 2020;150:4–11. (A large prospective study on postoperative radiotherapy in WHO grade 2–3 intracranial ependymomas in adults.)PubMedCrossRef
57.
Mansur DB, Perry A, Rajaram V, et al. Postoperative radiation therapy for grade II and III intracranial ependymoma. Int J Radiat Oncol Biol Phys. 2005;61(2):387–91.PubMedCrossRef
58.
Ghia AJ, Mahajan A, Allen PK, et al. Supratentorial gross-totally resected non-anaplastic ependymoma: population based patterns of care and outcomes analysis. J Neurooncol. 2013;115(3):513–20.PubMedCrossRef
59.
Han J, Yu M, Bai Y, et al. Elevated CXorf67 expression in PFA ependymomas suppresses DNA repair and sensitizes to PARP inhibitors. Cancer Cell. 2020;38(6):844-856.e7.PubMedPubMedCentralCrossRef
60.
• Donovan LK, Delaidelli A, Joseph SK, et al. Locoregional delivery of CAR T cells to the cerebrospinal fluid for treatment of metastatic medulloblastoma and ependymoma. Nat Med. 2020;26(5):720–31. (First report of a CAR T-cells immunotherapy for metastatic ependymoma.)PubMedPubMedCentralCrossRef
61.
Zacharoulis S, Ashley S, Moreno L, Gentet JC, Massimino M, Frappaz D. Treatment and outcome of children with relapsed ependymoma: a multi-institutional retrospective analysis. Childs Nerv Syst. 2010;26(7):905–11.PubMedCrossRef
62.
Marinoff AE, Ma C, Guo D, et al. Rethinking childhood ependymoma: a retrospective, multi-center analysis reveals poor long-term overall survival. J Neurooncol. 2017;135(1):201–11.PubMedPubMedCentralCrossRef
63.
64.
• Adolph JE, Fleischhack G, Mikasch R, et al. Local and systemic therapy of recurrent ependymoma in children and adolescents: short- and long-term results of the E-HIT-REZ 2005 study. Neuro Oncol. 2021;23(6):1012–23. (Final results of a prospective multicenter trial on local and systemic therapy in pediatric ependymomas.)PubMedCrossRef
65.
Gilbert MR, Rudà R, Soffietti R. Ependymomas in adults. Curr Neurol Neurosci Rep. 2010;10(3):240–7.PubMedCrossRef
66.
Kano H, Yang HC, Kondziolka D, et al. Stereotactic radiosurgery for pediatric recurrent intracranial ependymomas. J Neurosurg Pediatr. 2010;6(5):417–23.PubMedCrossRef
67.
Bouffet E, Hawkins CE, Ballourah W, et al. Survival benefit for pediatric patients with recurrent ependymoma treated with reirradiation. Int J Radiat Oncol Biol Phys. 2012;83(5):1541–8.PubMedCrossRef
68.
Hoffman LM, Plimpton SR, Foreman NK, et al. Fractionated stereotactic radiosurgery for recurrent ependymoma in children. J Neurooncol. 2014;116(1):107–11.PubMedPubMedCentralCrossRef
69.
Eaton BR, Chowdhry V, Weaver K, et al. Use of proton therapy for re-irradiation in pediatric intracranial ependymoma. Radiother Oncol. 2015;116(2):301–8.PubMedCrossRef
70.
• Tsang DS, Burghen E, Klimo P Jr, Boop FA, Ellison DW, Merchant TE. Outcomes after reirradiation for recurrent pediatric intracranial ependymoma. Int J Radiat Oncol Biol Phys. 2018;100(2):507–15. (An outereview retrospective analysis of reirradiation for recurrent ependymomas in children.)PubMedCrossRef
71.
Bouffet E, Foreman N. Chemotherapy for intracranial ependymomas. Childs Nerv Syst. 1999;15(10):563–70.PubMedCrossRef
72.
73.
Robison NJ, Campigotto F, Chi SN, et al. A phase II trial of a multi-agent oral antiangiogenic (metronomic) regimen in children with recurrent or progressive cancer. Pediatr Blood Cancer. 2014;61(4):636–42.PubMedCrossRef
74.
Jakacki RI, Foley MA, Horan J, et al. Single-agent erlotinib versus oral etoposide in patients with recurrent or refractory pediatric ependymoma: a randomized open-label study. J Neurooncol. 2016;129(1):131–8.PubMedCrossRef
75.
Komori K, Yanagisawa R, Miyairi Y, et al. Temozolomide treatment for pediatric refractory anaplastic ependymoma with low MGMT protein expression. Pediatr Blood Cancer. 2016;63(1):152–5.PubMedCrossRef
76.
Gururangan S, Chi SN, Young Poussaint T, et al. Lack of efficacy of bevacizumab plus irinotecan in children with recurrent malignant glioma and diffuse brainstem glioma: a Pediatric Brain Tumor Consortium study. J Clin Oncol. 2010;28(18):3069–75.PubMedPubMedCentralCrossRef
77.
DeWire M, Fouladi M, Turner DC, et al. An open-label, two-stage, phase II study of bevacizumab and lapatinib in children with recurrent or refractory ependymoma: a Collaborative Ependymoma Research Network study (CERN). J Neurooncol. 2015;123(1):85–91.PubMedPubMedCentralCrossRef
78.
Wetmore C, Daryani VM, Billups CA, et al. Phase II evaluation of sunitinib in the treatment of recurrent or refractory high-grade glioma or ependymoma in children: a Children’s Oncology Group study ACNS1021. Cancer Med. 2016;5(7):1416–24.PubMedPubMedCentralCrossRef
79.
Iqbal MS, Lewis J. An overview of the management of adult ependymomas with emphasis on relapsed disease. Clin Oncol (R Coll Radiol). 2013;25(12):726–33.CrossRef
80.
Rudà R, Bosa C, Magistrello M, et al. Temozolomide as salvage treatment for recurrent intracranial ependymomas of the adult: a retrospective study. Neuro Oncol. 2016;18(2):261–8.PubMedCrossRef
81.
Chamberlain MC, Johnston SK. Temozolomide for recurrent intracranial supratentorial platinum-refractory ependymoma. Cancer. 2009;115(20):4775–82.PubMedCrossRef
82.
Gilbert MR, Yuan Y, Wani K, et al. A phase II study of lapatinib and dosedense temozolomide (TMZ) for adults with recurrent ependymoma: a CERN clinical trial [Abstract]. Neuro Oncol. 2014;16(5):AT-23.
83.
Buccoliero AM, Castiglione F, Rossi Degl’Innocenti D, et al. O6-methylguanine-DNA-methyltransferase in recurring anaplastic ependymomas: PCR and immunohistochemistry. J Chemother. 2008;20(2):263–268.
84.
85.
Gornet MK, Buckner JC, Marks RS, Scheithauer BW, Erickson BJ. Chemotherapy for advanced CNS ependymoma. J Neurooncol. 1999;45(1):61–7.PubMedCrossRef
86.
Brandes AA, Cavallo G, Reni M, et al. A multicenter retrospective study of chemotherapy for recurrent intracranial ependymal tumors in adults by the Gruppo Italiano Cooperativo di Neuro-Oncologia. Cancer. 2005;104(1):143–8.PubMedCrossRef
87.
88.
• Deng Y, Chen H, Wang C, Zhang Y. Risk factors for the recurrence of world health organization grade II ependymomas of spinal cord in adults after microsurgical resections: a retrospective study of 118 patients in a single center. Clin Neurol Neurosurg. 2020;195:105856. (A huge retrospective study on the impact of modern surgery in grade 2 ependymomas of adult.)
89.
• Eroes CA, Zausinger S, Kreth FW, Goldbrunner R, Tonn JC. Intramedullary low grade astrocytoma and ependymoma. Surgical results and predicting factors for clinical outcome. Acta Neurochir (Wien). 2010;152(4):611–618. (Retrospective analysis of prognostic factors I intramedullary low grade ependymomas.)
90.
Lin Y, Smith ZA, Wong AP, Melkonian S, Harris DA, Lam S. Predictors of survival in patients with spinal ependymoma. Neurol Res. 2015;37(7):650–5.PubMedCrossRef
91.
Oh MC, Ivan ME, Sun MZ, et al. Adjuvant radiotherapy delays recurrence following subtotal resection of spinal cord ependymomas. Neuro Oncol. 2013;15(2):208–15.PubMedCrossRef
92.
Stermann A, Huebener N, Seidel D, et al. Targeting of MYCN by means of DNA vaccination is effective against neuroblastoma in mice. Cancer Immunol Immunother. 2015;64(10):1215–27.PubMedCrossRef
93.
94.
Weber DC, Wang Y, Miller R, et al. Long-term outcome of patients with spinal myxopapillary ependymoma: treatment results from the MD Anderson Cancer Center and institutions from the Rare Cancer Network. Neuro Oncol. 2015;17(4):588–95.PubMedCrossRef
95.
Bates JE, Choi G, Milano MT. Myxopapillary ependymoma: a SEER analysis of epidemiology and outcomes. J Neurooncol. 2016;129(2):251–8.PubMedCrossRef
96.
Akyurek S, Chang EL, Yu TK, et al. Spinal myxopapillary ependymoma outcomes in patients treated with surgery and radiotherapy at M.D. Anderson Cancer Center. J Neurooncol. 2006;80(2):177–183.
97.
Abdulaziz M, Mallory GW, Bydon M, et al. Outcomes following myxopapillary ependymoma resection: the importance of capsule integrity. Neurosurg Focus. 2015;39(2):E8.PubMedCrossRef
98.
• Montero AS, Tran S, Amelot A, et al. Clinical characteristics and long-term surgical outcome of spinal myxopapillary ependymoma: a French cohort of 101 patients. J Neurooncol. 2021;152(3):491–9. (Multi-institutional study on outcome of myxopapillary spinal ependymoma.)PubMedCrossRef
99.
• Liu T, Yang C, Deng X, et al. Clinical characteristics and surgical outcomes of spinal myxopapillary ependymomas. Neurosurg Rev. 2020;43(5):1351–6. (Retrospective analysis of outcome after surgery for myxopapillary ependymoma.)PubMedCrossRef
100.
Feldman WB, Clark AJ, Safaee M, Ames CP, Parsa AT. Tumor control after surgery for spinal myxopapillary ependymomas: distinct outcomes in adults versus children: a systematic review. J Neurosurg Spine. 2013;19(4):471–6.PubMedCrossRef
101.
Schild SE, Wong W, Nisi K. In regard to the radiotherapy of myxopapillary ependymomas. Int J Radiat Oncol Biol Phys. 2002;53(3):787.PubMedCrossRef
102.
Bandopadhayay P, Silvera VM, Ciarlini PDSC, et al. Myxopapillary ependymomas in children: imaging, treatment and outcomes. J Neurooncol. 2016;126(1):165–74.PubMedCrossRef
103.
Lucchesi KM, Grant R, Kahle KT, Marks AM, DiLuna ML. Primary spinal myxopapillary ependymoma in the pediatric population: a study from the Surveillance, Epidemiology, and End Results (SEER) database. J Neurooncol. 2016;130(1):133–40.PubMedCrossRef
104.
Al-Halabi H, Montes JL, Atkinson J, Farmer JP, Freeman CR. Adjuvant radiotherapy in the treatment of pediatric myxopapillary ependymomas. Pediatr Blood Cancer. 2010;55(4):639–43.PubMedCrossRef
105.
Agbahiwe HC, Wharam M, Batra S, Cohen K, Terezakis SA. Management of pediatric myxopapillary ependymoma: the role of adjuvant radiation. Int J Radiat Oncol Biol Phys. 2013;85(2):421–7.PubMedCrossRef
Metadata
Title
Ependymoma: Evaluation and Management Updates
Authors
Roberta Rudà
Francesco Bruno
Alessia Pellerino
Riccardo Soffietti
Publication date
06-04-2022
Publisher
Springer US
Published in
Current Oncology Reports / Issue 8/2022
Print ISSN: 1523-3790
Electronic ISSN: 1534-6269
DOI
https://doi.org/10.1007/s11912-022-01260-w

Other articles of this Issue 8/2022

Current Oncology Reports 8/2022 Go to the issue

Pediatric Oncology (KL Davis, Section Editor)

Neuroblastoma Heterogeneity, Plasticity, and Emerging Therapies

Leukemia (A Aguayo, Section Editor)

Controversies in the Treatment of Adolescents and Young Adults with Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia

Interventional Oncology (DC Madoff, Section Editor)

Thermal Ablation for the Management of Papillary Thyroid Microcarcinoma in the Era of Active Surveillance and Hemithyroidectomy

Anesthesiology and Critical Care (JP Cata, Section Editor)

Managing Pain and Discomfort in Children with Cancer

Melanoma (DB Johnson, Section Editor)

Triplet Therapy in Melanoma — Combined BRAF/MEK Inhibitors and Anti-PD-(L)1 Antibodies

Lymphomas (T Hilal, Section Editor)

Richter’s Transformation
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits